HCV antiviral resistance: The impact of in vitro studies on the development of antiviral agents targeting the viral NS5B polymerase

Antiviral Chemistry and Chemotherapy

Volumn 16, Issue 4, 2005, Pages 225-245

  Tomei, Licia ^a   Altamura, Sergio ^a   Paonessa, Giacomo ^a   De Francesco, Raffaele ^a   Migliaccio, Giovanni ^a  

^a IRBM   (Italy)

Author keywords

Allosteric inhibitors; HCV; Hepatitis C; NNI; NS5B; Nucleoside analogue; Pyrophosphate mimic; RdRp; Resistance; RNA dependent RNA polymerase

Indexed keywords

2' C METHYLADENOSINE; 2' C METHYLGUANOSINE; 2' O METHYLCYTIDINE; ALPHA GAMMA DIKETO ACID; ANTIVIRUS AGENT; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; FOSCARNET; JTK 003; NM 107; NS5B POLYMERASE; PEGINTERFERON; PHENYLALANINE DERIVATIVE; PYROPHOSPHORIC ACID DERIVATIVE; RECOMBINANT ALPHA INTERFERON; RIBAVIRIN; RNA POLYMERASE; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG; VALOPICITABINE; VIRUS ENZYME;

ANTIVIRAL ACTIVITY; BLOOD DISEASE; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME STRUCTURE; FLU LIKE SYNDROME; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; HALF LIFE TIME; HEPATITIS C; HEPATITIS C VIRUS; HIGH THROUGHPUT SCREENING; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; MENTAL DISEASE; MUTATION RATE; NEUROLOGIC DISEASE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN FUNCTION; REPLICON; REVIEW; STRUCTURE ACTIVITY RELATION; VIRUS GENOME; VIRUS LOAD;

EID: 23744446809     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020501600403     Document Type: Review

References (123)

1. Adachi T, Ago H, Habuka N, Okuda K, Komatsu M, Ikeda S & Yatsunami K (2002) The essential role of C-terminal residues in regulating the activity of hepatitis C virus RNA-dependent RNA polymerase. Biochemica et Biophysica Acta 1601:38-48.
2. Afdhal N, Godofsky E, Dienstag J, Rustgi V, Schick L, McEniry D, Xhou X-J, Chao G, Fang C, Fielman B, Myers M & Brown N (2004) Final phase I/II trial results for NM283, a new polymerase inhibitor for hepatitis C: antiviral efficacy and tolerance in patients with HCV-1 infection, including previous interferon failures. Hepatology 50(Suppl):127.
3. Ago H, Adachi T, Yoshida A, Yamamoto M, Habuka N, Yatsunami K & Miyano M (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Structure 7:1417-1426.
4. Ali S, Pellerin C, Lamarre D & Kukolj G (2004) Hepatitis C virus subgenomic replicons in the human embryonic kidney 293 cell line. Journal of Virology 78:491-501.
5. Altamura S, Tomei L, Koch U, Neuner PJS & Summa V (2000) Diketoacid derivatives as inhibitors of viral polymerases. PCT International Application 2000006529.
6. Avolio S, Di Filippo M, Harper S, Narjes F, Pacini B, Pompei M, Rowley M & Stansfield I (2004) Preparation of indole acetamides as inhibitors of the hepatitis c virus NS5B polymerase. PCT International Application 2004087714.
7. Bacon BR (2004) Managing hepatitis C. The American Journal of Managed Care 10:S30-40.
8. Bartenschlager R (2002) Hepatitis C virus replicons: potential role for drug development. Nature Reviews Drug Discovery 1:911-916.
9. Bartenschlager R, Ahlborn-Laake L, Mous J & Jacobsen H (1993) Nonstructural protein 3 of the hepatitis C virus encodes a serine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. Journal of Virology 67:3835-3844.
10. Bartosch B, Dubuisson J & Cosset FL (2003) Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. Journal of Experimental Medicine 197:633-642.
11. Beaulieu PL, Bos M, Bousquet Y, DeRoy P, Fazal G, Gauthier J, Gillard J, Goulet S, McKercher G, Poupart MA, Valois S & Kukolj G (2004a) Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery of benzimidazole 5-carboxylic amide derivatives with low-nanomolar potency. Bioorganic & Medicinal Chemistry Letters 14:967-971.
12. Beaulieu PL, Brochu C, Chabot C, Jolicoeur E, Kawai S, Poupart M-A & Tsantrizos YS (2004b) Preparation of indole-6-carboxylic acids and related compounds as hepatitis C viral polymerase inhibitors. PCT International Application 2004065367.
13. Behrens SE, Tomei L & De Francesco R (1996) Identification and properties of the RNA-dependent RNA polymerase of hepatitis C virus. Embo Journal 15:12-22.
14. Biswal BK, Cherney MM, Wang M, Chan L, Yannopoulos CG, Bilimoria D, Nicolas O, Bedard J & James MN (2005) Crystal structures of the RNA dependent RNA polymerase genotype 2a of hepatitis C virus reveal two conformations and suggest mechanisms of inhibition by non-nucleoside inhibitors. Journal of Biological Chemistry 280:18202-18210.
15. Blight KJ, Kolykhalov AA & Rice CM (2000) Efficient initiation of HCV RNA replication in cell culture. Science 290:1972-1974.
16. Blight KJ, McKeating JA & Rice CM (2002) Highly permissive cell lines for subgenomic and genomic hepatitis C virus RNA replication. Journal of Virology 76:13001-13014.
17. Bougie I & Bisaillon M (2003) Initial binding of the broad spectrum antiviral nucleoside ribavirin to the hepatitis C virus RNA polymerase. Journal of Biological Chemistry 278:52471-52478.
18. Bressanelli S, Tomei L, Rey FA & De Francesco R (2002) Structural analysis of the hepatitis C virus RNA polymerase in complex with ribonucleotides. Journal of Virology 76:3482-3492.
19. Bressanelli S, Tomei L, Roussel A, Incitti I, Vitale RL, Mathieu M, De Francesco R & Rey FA (1999) Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proceedings of the National Academy of Sciences, USA 96:13034-13039.
20. Bukh J, Pietschmann T, Lohmann V, Krieger N, Faulk K, Engle RE, Govindarajan S, Shapiro M, St Claire M & Bartenschlager R (2002) Mutations that permit efficient replication of hepatitis C virus RNA in Huh-7 cells prevent productive replication in chimpanzees. Proceedings of the National Academy of Sciences, USA 99:14416-14421.
21. Butcher SJ, Grimes JM, Makeyev EV, Bamford DH & Stuart DI (2001) A mechanism for initiating RNA-dependent RNA polymerization. Nature 410:235-240.
22. Carroll S, Bailey C, Bosserman M, Burlein C, Simcoe A, Fay J, Ludmerer S, Graham D, LaFemina R, Flores O, Hazuda D, Altamura S, Migliaccio G, Tomei L, De-Francesco R, Summa V & Olsen D (2004) Susceptibility of different genotypes of hepatitis C Virus to inhibition by nucleoside and nonnucleoside inhibitors. Antiviral Research 62:A83.
23. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M & Olsen DB (2003) Inhibition of hepatitis C virus RNA replication by 2′-modified nucleoside analogs. Journal of Biological Chemistry 278:11979-11984.
24. Chan L, Das SK, Reddy TJ, Poisson C, Proulx M, Pereira O, Courchesne M, Roy C, Wang W, Siddiqui A, Yannopoulos CG, Nguyen-Ba N, Labrecque D, Bethell R, Hamel M, Courtemanche-Asselin P, L'Heureux L, David M, Nicolas O, Brunette S, Bilimoria D & Bedard J (2004a) Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides. Bioorganic & Medicinal Chemistry Letters 14:793-796.
25. Chan L, Pereira O, Reddy TJ, Das SK, Poisson C, Courchesne M, Proulx M, Siddiqui A, Yannopoulos CG, Nguyen-Ba N, Roy C, Nasturica D, Moinet C, Bethell R, Hamel M, L'Heureux L, David M, Nicolas O, Courtemanche-Asselin P, Brunette S, Bilimoria D & Bedard J (2004b) Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides. Bioorganic & Medicinal Chemistry Letters 14:797-800.
26. Chander G, Sulkowski MS, Jenckes MW, Torbenson MS, Herlong HF, Bass EB & Gebo KA (2002) Treatment of chronic hepatitis C: a systematic review. Hepatology 36:8135-144.
27. Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW & Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 244:359-362.
28. Contreras AM, Hiasa Y, He W, Terella A, Schmidt EV & Chung RT (2002) Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. Journal of Virology 76:8505-8517.
29. Coulombe R, Beaulieu PL, Jolicoeur E, Kukolj G, Lapante S & Poupart MA (2004) Crystal structure of hepatitis C virus NS5B polymerase inhibitor binding pocket for drug design and screening. 2004099241 PCT int appl, 413 pp.
30. Date T, Kato T, Miyamoto M, Zhao Z, Yasui K, Mizokami M & Wakita T (2004) Genotype 2a hepatitis C virus subgenomic replicon can replicate in HepG2 and IMY-N9 cells. Journal of Biological Chemistry 279:22371-22376.
31. De Clercq E (2004) Antiviral drugs in current clinical use. Journal of Clinical Virology 30:115-133.
32. De Francesco R, Tomei L, Altamura S, Summa V & Migliaccio G (2003) Approaching a new era for hepatitis C virus therapy: inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Research 58:1-16.
33. Dhanak D, Duffy KJ, Johnston VK, Lin-Goerke J, Darcy M, Shaw AN, Gu B, Silverman C, Gates AT, Nonnemacher MR, Earnshaw DL, Casper DJ, Kaura A, Baker A, Greenwood C, Gutshall LL, Maley D, DelVecchio A, Macarron R, Hofmann GA, Alnoah Z, Cheng HY, Chan G, Khandekar S, Keenan RM & Sarisky RT (2002) Identification and biological characterization of heterocyclic inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Journal of Biological Chemistry 277:38322-38327.
34. Dhanak D, Kaura AC & Shaw A (2001) Preparation of 3-(1,1-dioxo-2H-benzo-1,2,4-thiadiazin-3-yl)-2-quinolones as novel anti-infectives. PCT International Application 0185172.
35. Di Bisceglie AM & Hoofnagle JH (2002) Optimal therapy of hepatitis C. Hepatology 36:S121-127.
36. Di Marco S, Volpari C, Tomei L, Altamura S, Harper S, Narjes F, Koch U, Rowley M, De Francesco R, Migliaccio G & Carfi A (2005) Interdomain communication in hepatitis C virus polymerase abolished by small-molecule inhibitors bound to a novel allosteric site. Journal of Biological Chemistry: in press.
37. Egger D, Wolk B, Gosert R, Bianchi L, Blum HE, Moradpour D & Bienz K (2002) Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex. Journal of Virology 76:5974-5984.
38. Einav S, Elazar M, Danieli T & Glenn JS (2004) A nucleotide binding motif in hepatitis C virus (HCV) NS4B mediates HCV RNA replication. Journal of Virology 78:11288-11295.
39. Eldrup AB, Allerson CR, Bennett CF, Bera S, Bhat B, Bhat N, Bosserman MR, Brooks J, Burlein C, Carroll SS, Cook PD, Getty KL, MacCoss M, McMasters DR, Olsen DB, Prakash TP, Prhavc M, Song Q, Tomassini JE & Xia J (2004) Structure-activity relationship of purine ribonucleosides for inhibition of hepatitis C virus RNA-dependent RNA polymerase. Journal of Medicinal Chemistry 47:2283-2295.
40. Ferrari E, Wright-Minogue J, Fang JW, Baroudy BM, Lau JY & Hong Z (1999) Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. Journal of Virology 73:1649-1654.
41. Flint M, Quinn ER & Levy S (2001) In search of hepatitis C virus receptor(s). Clinical Liver Disease 5:873-893.
42. Friebe P, Lohmann V, Krieger N & Bartenschlager R (2001) Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication. Journal of Virology 75:12047-57.
43. Godofsky E, Afdhal N, Rustgi V, Shick L, Duncan L, Zhou XJ, Chao G, Fang C, Fielman B, Myers M & Brown N (2004) First clinical results for a novel antiviral treatment for hepatitis C: A phase I/II dose escalation trial assessing tolerance, pharmacokinetics, and antiviral activity of NM283. Journal of Hepatology 40(Suppl. 1):35.
44. Grakoui A, McCourt DW, Wychowski C, Feinstone SM & Rice CM (1993a) Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. Journal of Virology 67:2832-2843.
45. Grakoui A, McCourt DW, Wychowski C, Feinstone SM & Rice CM (1993b) A second hepatitis C virus-encoded proteinase. Proceedings of the National Academy of Sciences, USA 90:10583-10587.
46. Griffin SD, Beales LP, Clarke DS, Worsfold O, Evans SD, Jaeger J, Harris MP & Rowlands DJ (2003) The p7 protein of hepatitis C virus forms an ion channel that is blocked by the antiviral drug Amantadine. FEBS Letters 535:34-38.
47. Grobler JA, Stillmock K, Hu B, Witmer M, Felock P, Espeseth AS, Wolfe A, Egbertson M, Bourgeois M, Melamed J, Wai JS, Young S, Vacca J & Hazuda DJ (2002) Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes. Proceedings of the National Academy of Sciences, USA 99:6661-6666.
48. Gu B, Johnston VK, Gutshall LL, Nguyen TT, Gontarek RR, Darcy MG, Tedesco R, Dhanak D, Duffy KJ, Kao CC & Sarisky RT (2003) Arresting initiation of hepatitis C virus RNA synthesis using heterocyclic derivatives. Journal of Biological Chemistry 278:16602-16607.
49. Harper S, Pacini B, Avolio S, Di Filippo M, Migliaccio G, Laufer R, De Francesco R, Rowley M & Narjes F (2005) Development and preliminary optimization of indole-N-acetamide inhibitors of hepatitis C virus NS5B polymerase. Journal of Medicinal Chemistry 48:1314-1317.
50. Hashimoto H, Mizutani K & Yoshida A (2001) Preparation of heterocyclic compounds as remedies for hepatitis C. Published International Patent Application WO 00147883.
51. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C & Miller MD (2000) Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 287:646-650.
52. Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K & Shimotohno K (1993a) Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. Journal of Virology 67:4665-4675.
53. Hijikata M, Mizushima H, Tanji Y, Komoda Y, Hirowatari Y, Akagi T, Kato N, Kimura K & Shimotohno K (1993b) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proceedings of the National Academy of Sciences, USA 90:10773-10777.
54. Hong Z, Cameron CE, Walker MP, Castro C, Yao N, Lau JY & Zhong W (2001) A novel mechanism to ensure terminal initiation by hepatitis C virus NS5B polymerase. Virology 285:6-11.
55. Houghton M (1996) Hepatitis C viruses. In Virology, vol. 1; pp. 1035-1058. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia, New York: Lippincott-Raven.
56. Hsu M, Zhang J, Flint M, Logvinoff C, Cheng-Mayer C, Rice CM & McKeating JA (2003) Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proceedings of the National Academy of Sciences, USA 100:7271-7276.
57. Hugle T, Fehrmann F, Bieck E, Kohara M, Krausslich HG, Rice CM, Blum HE & Moradpour D (2001) The hepatitis C virus nonstructural protein 4B is an integral endoplasmic reticulum membrane protein. Virology 284:70-81.
58. Johnson RB, Sun XL, Hockman MA, Villarreal EC, Wakulchik M & Wang QM (2000) Specificity and mechanism analysis of hepatitis C virus RNA-dependent RNA polymerase. Archives of Biochemistry and Biophysics 377:129-134.
59. Johnston VK, Maley D, Gagnon RC, Grassmann CW, Behrens SE & Sarisky RT (2003) Kinetic profile of a heterocyclic HCV replicon RNA synthesis inhibitor. Biochemical and Biophysical Research Communications 311:672-677.
60. Kao CC, Yang X, Kline A, Wang QM, Barket D & Heinz BA (2000) Template requirements for RNA synthesis by a recombinant hepatitis C virus RNA-dependent RNA polymerase. Journal of Virology 74:11121-11128.
61. Kato T, Date T, Miyamoto M, Furusaka A, Tokushige K, Mizokami M & Wakita T (2003) Efficient replication of the genotype 2a hepatitis C virus subgenomic replicon. Gastroenterology 125:1808-1817.
62. Kim DW, Gwack Y, Han JH & Choe J (1995) C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochemical and Biophysical Research Communications 215:160-166.
63. Kim M, Kim H, Cho SP & Min MK (2002) Template requirements for de novo RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase on the viral X RNA. Journal of Virology 76:6944-6956.
64. Kolykhalov AA, Agapov EV, Blight KJ, Mihalik K, Feinstone SM & Rice CM (1997) Transmission of hepatitis C by intrahepatic inoculation with transcribed RNA. Science 277:570-574.
65. LaPlante SR, Jakalian A, Aubry N, Bousquet Y, Ferland JM, Gillard J, Lefebvre S, Poirier M, Tsantrizos YS, Kukolj G & Beaulieu PL (2004) Binding mode determination of benzimidazole inhibitors of the hepatitis C virus RNA polymerase by a structure and dynamics strategy. Angewandte Chemie International Edition 43:4306-4311.
66. Lau JY, Tam RC, Liang TJ & Hong Z (2002) Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 35:1002-1009.
67. Lee KJ, Choi J, Ou JH & Lai MM (2004) The C-terminal transmembrane domain of hepatitis C virus (HCV) RNA polymerase is essential for HCV replication in vivo. Journal of Virology 78:3797-3802.
68. Lesburg CA, Cable MB, Ferrari E, Hong Z, Mannarino AF & Weber PC (1999) Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nature Structural Biology 6:937-943.
69. Lin C, Lin K, Luong YP, Rao BG, Wei YY, Brennan DL, Fulghum JR, Hsiao HM, Ma S, Maxwell JP, Cottrell KM, Perni RB, Gates CA & Kwong AD (2004) In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. Journal of Biological Chemistry 279:17508-17514.
70. Lindenbach BD, Evans MJ, Syder AJ, Wolk B, Tellinghuisen TL, Liu CC, Maruyama T, Hynes RO, Burton DR, McKeating JA & Rice CM (2005) Complete replication of hepatitis C virus in cell culture. Science: in press.
71. Lohmann V, Korner F, Herian U & Bartenschlager R (1997) Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity. Journal of Virology 71:8416-8428.
72. Lohmann V, Korner F, Koch J, Herian U, Theilmann L & Bartenschlager R (1999) Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 285:110-113.
73. Love RA, Parge HE, Yu X, Hickey MJ, Diehl W, Gao J, Wriggers H, Ekker A, Wang L, Thomson JA, Dragovich PS & Fuhrman SA (2003) Crystallographic identification of a noncompetitive inhibitor binding site on the hepatitis C virus NS5B RNA polymerase enzyme. Journal of Virology 77:7575-7581.
74. Ludmerer SW, Graham DJ, Boots E, Murray EM, Simcoe A, Markel EJ, Grobler JA, Flores OA, Olsen DB, Hazuda DJ & Lafemina RL (2005a) Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay. Antimicrobial Agents and Chemotherapy 49:2059-2069.
75. Luo G, Hamatake RK, Mathis DM, Racela J, Rigat KL, Lemm J & Colonno RJ (2000) De novo initiation of RNA synthesis by the RNA-dependent RNA polymerase (NS5B) of hepatitis C virus. Journal of Virology 74:851-863.
76. Maag D, Castro C, Hong Z & Cameron CE (2001) Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. Journal of Biological Chemistry 276:46094-46098.
77. McHutchison JG (2004) Understanding hepatitis C. The American Journal of Managed Care 10:S21-9.
78. McHutchison JG & Patel K (2002) Future therapy of hepatitis C. Hepatology 36:S245-52.
79. McKercher G, Beaulieu PL, Lamarre D, LaPlante S, Lefebvre S, Pellerin C, Thauvette L & Kukolj G (2004) Specific inhibitors of HCV polymerase identified using an NS5B with lower affinity for template/primer substrate. Nucleic Acids Research 32:422-431.
80. McLauchlan J (2000) Properties of the hepatitis C virus core protein: a structural protein that modulates cellular processes. Journal of Viral Hepatitis 7:2-14.
81. Migliaccio G, Tomassini JE, Carroll SS, Tomei L, Altamura S, Bhat B, Bartholomew L, Bosserman MR, Ceccacci A, Colwell LF, Cortese R, De Francesco R, Eldrup AB, Getty KL, Hou XS, LaFemina RL, Ludmerer SW, MacCoss M, McMasters DR, Stahlhut MW, Olsen DB, Hazuda DJ & Flores OA (2003) Characterization of resistance to non-obligate chain-terminating ribonucleoside analogs that inhibit hepatitis C virus replication in vitro. Journal of Biological Chemistry 278:49164-49170.
82. Nguyen TT, Gates AT, Gutshall LL, Johnston VK, Gu B, Duffy KJ & Sarisky RT (2003) Resistance profile of a hepatitis C virus RNA-dependent RNA polymerase benzothiadiazine inhibitor. Antimicrobial Agents and Chemotherapy 47:3525-3530.
83. O'Farrell D, Trowbridge R, Rowlands D & Jager J (2003) Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de novo initiation. Journal of Molecular Biology 326:1025-1035.
84. Oh JW, Sheu GT & Lai MM (2000) Template requirement and initiation site selection by hepatitis C virus polymerase on a minimal viral RNA template. Journal of Biological Chemistry 275:17710-17717.
85. Olsen DB, Eldrup AB, Bartholomew L, Bhat B, Bosserman MR, Ceccacci A, Colwell LF, Fay JF, Flores OA, Getty KL, Grobler JA, LaFemina RL, Markel EJ, Migliaccio G, Prhavc M, Stahlhut MW, Tomassini JE, MacCoss M, Hazuda DJ & Carroll SS (2004) A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrobial Agents and Chemotherapy 48:3944-3953.
86. Pavlovic D, Neville DC, Argaud O, Blumberg B, Dwek RA, Fischer WB & Zitzmann N (2003) The hepatitis C virus p7 protein forms an ion channel that is inhibited by long-alkyl-chain iminosugar derivatives. Proceedings of the National Academy of Sciences, USA 100:6104-6108.
87. Pieroni L, Santolini E, Fipaldini C, Pacini L, Migliaccio G & La Monica N (1997) In vitro study of the NS2-3 protease of hepatitis C virus. Journal of Virology 71:6373-6380.
88. Pileri P, Uematsu Y, Campagnoli S, Galli G, Falugi F, Petracca R, Weiner AJ, Houghton M, Rosa D, Grandi G & Abrignani S (1998) Binding of hepatitis C virus to CD81. Science 282:938-941.
89. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH & Albrecht J (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303-1313.
90. Rice CM (1996) Flaviviridae, the viruses and their replication. In Virology, vol. 1; pp. 1035-1058. Edited by BN Fields, DM Knipe & PM Howley. Philadelphia, New York: Lippincott-Raven.
91. Sakai A, Claire MS, Faulk K, Govindarajan S, Emerson SU, Purcell RH & Bukh J (2003) The p7 polypeptide of hepatitis C virus is critical for infectivity and contains functionally important genotype-specific sequences. Proceedings of the National Academy of Sciences, USA 100:11646-11651.
92. Santolini E, Migliaccio G & La Monica N (1994) Biosynthesis and biochemical properties of the hepatitis C virus core protein. Journal of Virology 68:3631-3641.
93. Scarselli E, Ansuini H, Cerino R, Roccasecca RM, Acali S, Filocamo G, Traboni C, Nicosia A, Cortese R & Vitelli A (2002) The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. Embo Journal 21:5017-5025.
94. Shaw-Reid CA, Munshi V, Graham P, Wolfe A, Witmer M, Danzeisen R, Olsen DB, Carroll SS, Embrey M, Wai JS, Miller MD, Cole JL & Hazuda DJ (2003) Inhibition of HIV-1 ribonuclease H by a novel diketo acid, 4-[5-(benzoylamino) thien-2-yl]-2,4-dioxobutanoic acid. Journal of Biological Chemistry 278:2777-2780.
95. Shim JH, Larson G, Wu JZ & Hong Z (2002) Selection of 3′-template bases and initiating nucleotides by hepatitis C virus NS5B RNA-dependent RNA polymerase. Journal of Virology 76:7030-7039.
96. Simmonds P, Holmes EC, Cha TA, Chan SW, McOmish F, Irvine B, Beall E, Yap PL, Kolberg J & Urdea MS (1993) Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region. Journal of General Virology 74:2391-2399.
97. Standring DN, Lanford R, Wright T, Chung RT, Bichko V, Cretton-Scott E, Pan-Zhou X, Bergelson S, Qu L, Tausek M, Bridges, Moussa A, Storer R, Pierra C, Benzaria S, Gosselin G, La Colla P, Sommadossi JP (2003) NM 283 has potent antiviral activity against genotype 1 chronic hepatitis C virus (HCV-1) infection in the chimpanzee. Journal of Hepatology 38(Suppl 2):3.
98. Summa V, Petrocchi A, Matassa VG, Taliani M, Laufer R, De Francesco R, Altamura S & Pace P (2004a) HCV NS5b RNA-dependent RNA polymerase inhibitors: from alpha,gamma-diketoacids to 4,5-dihydroxypyrimidine- or 3-methyl-5-hydroxypyrimidinonecarboxylic acids. Design and synthesis. Journal of Medicinal Chemistry 47:5336-5339.
99. Summa V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S, Tomei L, Koch U & Neuner P (2004b) Discovery of alpha,gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. Journal of Medicinal Chemistry 47:14-17.
100. Sundquist B & Oberg B (1979) Phosphonoformate inhibits reverse transcriptase. Journal of General Virology 45:273-281.
101. Summer V, Petrocchi A, Pace P, Matassa VG, De Francesco R, Altamura S, Tomei L, Koch U & Neuner P (2004b) Discovery of alpha, gamma-diketo acids as potent selective and reversible inhibitors of hepatitis C virus NS5b RNA-dependent RNA polymerase. Journal of Medicinal Chemistry 47:14-17.
102. Tan SL & Katze MG (2001) How hepatitis C virus counteracts the interferon response: the jury is still out on NS5A. Virology 284:1-12.
103. Tanaka T, Kato N, Cho MJ & Shimotohno K (1995) A novel sequence found at the 3′ terminus of hepatitis C virus genome. Biochemical and Biophysical Research Communications 215:744-749.
104. Tanji Y, Kaneko T, Satoh S & Shimotohno K (1995) Phosphorylation of hepatitis C virus-encoded nonstructural protein NS5A. Journal of Virology 69:3980-3986.
105. Tellinghuisen TL, Marcotrigiano J, Gorbalenya AE & Rice CM (2004) The NS5A protein of hepatitis C virus is a zinc metalloprotein. Journal of Biological Chemistry 279:48576-48587.
106. Tomassini J, Selnick H, Davies ME, Armstrong ME, Baldwin J, Bourgeois M, Hastings J, Hazuda D, Lewis J, McClements W, Ponticello G, Radzilowski E, Smith G, Tebben A & Wolfe A (1994) Inhibition of cap (m7GpppXm)-dependent endonuclease of influenza virus by 4-substituted 2,4-dioxobutanoic acid compounds. Antimicrobial Agents & Chemotherapy 38:2827-2837.
107. Tomei L, Altamura S, Bartholomew L, Biroccio A, Ceccacci A, Pacini L, Narjes F, Gennari N, Bisbocci M, Incitti I, Orsatti L, Harper S, Stansfield I, Rowley M, De Francesco R & Migliaccio G (2003) Mechanism of action and antiviral activity of benzimidazole-based allosteric inhibitors of the hepatitis C virus RNA-dependent RNA polymerase. Journal of Virology 77:13225-13231.
108. Tomei L, Altamura S, Bartholomew L, Bisbocci M, Bailey C, Bosserman M, Cellucci A, Forte E, Incitti I, Orsatti L, Koch U, De Francesco R, Olsen DB, Carroll SS & Migliaccio G (2004) Characterization of the inhibition of hepatitis C virus RNA replication by nonnucleosides. Journal of Virology 78:938-946.
109. Tomei L, Failla C, Santolini E, De Francesco R & La Monica N (1993) NS3 is a serine protease required for processing of hepatitis C virus polyprotein. Journal of Virology 67:4017-4026.
110. Tomei L, Vitale RL, Incitti I, Serafmi S, Altamura S, Vitelli A & De Francesco R (2000) Biochemical characterization of a hepatitis C virus RNA-dependent RNA polymerase mutant lacking the C-terminal hydrophobic sequence. Journal of General Virology 81:759-767.
111. Trozzi C, Bartholomew L, Ceccacci A, Biasiol G, Pacini L, Altamura S, Narjes F, Muraglia E, Paonessa G, Koch U, De Francesco R, Steinkuhler C & Migliaccio G (2003) In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor. Journal of Virology 77:3669-3679.
112. Tsukiyama-Kohara K, Iizuka N, Kohara M & Nomoto A (1992) Internal ribosome entry site within hepatitis C virus RNA. Journal of Virology 66:1476-1483.
113. Wakita T, Pietschmann T, Kato T, Date T, Miyamoto M, Zhao Z, Murthy K, Habermann A, Krausslich HG, Mizokami M, Bartenschlager R & Liang TJ (2005) Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine: in press.
114. Walewski JL, Keller TR, Stump DD & Branch AD (2001) Evidence for a new Hepatitis C virus antigen encoded in an overlapping reading frame. RNA 7:710-721.
115. Wang M, Ng KK, Cherney MM, Chan L, Yannopoulos CG, Bedard J, Morin N, Nguyen-Ba N, Alaoui-Ismaili MH, Bethell RC & James MN (2003) Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. Journal of Biological Chemistry 278:9489-9495.
116. Wasley A & Alter MJ (2000) Epidemiology of hepatitis C: geographic differences and temporal trends. Seminars in Liver Disease 20:1-16.
117. Wu JZ & Hong Z (2003) Targeting NS5B RNA-dependent RNA polymerase for anti-HCV chemotherapy. Current Drug Targets: Infectious Disorders 3:207-219.
118. Xu Z, Choi J, Yen TS, Lu W, Strohecker A, Govindarajan S, Chien D, Selby MJ & Ou J (2001) Synthesis of a novel hepatitis C virus protein by ribosomal frameshift. Embo Journal 20:3840-3848.
119. Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL & Lai MM (2003) Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. Hepatology 38:869-878.
120. Zhong J, Gastaminza P, Cheng G, Kapadia S, Kato T, Burton DR, Wieland SF, Uprichard SL, Wakita T & Chisari FV (2005) Robust hepatitis C virus infection in vitro. Proceedings of the National Academy of Sciences, USA 102:9294-9299.
121. Zhong W, Uss AS, Ferrari E, Lau JY & Hong Z (2000) De novo initiation of RNA synthesis by hepatitis C virus nonstructural protein 5B polymerase. Journal of Virology 74:2017-2022.
122. Zhou S, Liu R, Baroudy BM, Malcolm BA & Reyes GR (2003) The effect of ribavirin and IMPDH inhibitors on hepatitis C virus subgenomic replicon RNA. Virology 310:333-342.
123. Zhu Q, Guo JT & Seeger C (2003) Replication of hepatitis C virus subgenomes in nonhepatic epithelial and mouse hepatoma cells. Journal of Virology 77:9204-9210.